MyoKardia's Mavacamten 'Impressive' In Hypertrophic Cardiomyopathy

Launch Planning Underway For The Biotech's Lead Candidate

Sep 01 2020

• By John Davis

Listen to this article

MyoKardia is building up its organization to prepare for commercialization of mavacamten, a potential first-in-class agent for obstructive hypertrophic cardiomyopathy.

Cardiomyopathy — • Source: Shutterstock

Updated results from the Phase III EXPLORER-HCM trial have continued to portray the clinical benefits of MyoKardia, Inc.’s mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (HCM). With a US new drug application expected to be submitted in the first quarter of 2021, the Brisbane, CA-based company has sketched out commercialization plans for its lead first-in-class therapeutic candidate.

Mavacamten has the potential to be the first therapeutic candidate to target excessive contractility and impaired relaxation associated with obstructive...

More from Cardiovascular

Aerovate Tanks On Trial Catastrophe
Mar 10 2025
• By Elizabeth Cairns
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
Kerendia Could Be Next Jewel In Bayer's Pharma Crown
Mar 10 2025
• By Kevin Grogan
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.